NJ Bio, Inc. was pleased to welcome Dr. Yutaka Matsuda and his colleague Mr. Hiroki Imai (Business Development Manager) from Ajinomoto Bio-Pharma Services to our headquarters in Princeton. Dr. Yutaka Matsuda is a double Ph.D. and an expert in site-specific chemical conjugation technology. At Ajinomoto Bio-Pharma services, he has played an integral part in the development of the proprietary AJICAP® Site-Specific Conjugation technology. He is also an originator of the novel linker technology AJICAP® Stable and Hydrophilic Linker. He is listed as the first or corresponding author of more than 30 publications (including over 20 ADC-related papers) and has a deep expertise in ADC conjugation chemistry and synthetic chemistry. NJ Bio has a long-standing collaboration with Ajinomoto Bio-Pharma Services and has been able to contribute significantly to advancement of their technology.
Dr. Matsuda presented on “AJICAP®: An Innovative Direct Chemical Site-Directed Conjugation Method for Intact Native Antibodies”. His talk focused on the advantages of using the AJICAP® platform for designing next generation ADCs. The AJICAP® conjugation technology is based on the affinity peptide approach and shows significant advantages in designing site-specific ADCs. This platform works to improve the therapeutic window, devise a straight-forward method for site-specific conjugation and shows applications to versatile ADCs. He also elaborated on the AJICAP® Linker, a novel stable and hydrophilic linker which is applicable to various payloads.
The entire team at NJ Bio was extremely grateful to Dr. Matsuda for sharing his deep insights on Ajinomoto’s proprietary technology and discussing various strategies and advances in developing next generation ADCs.